Petros Pharmaceuticals, Inc. in brief
Petros Pharmaceuticals, Inc. is a listed company in the Pharmaceutical industry, based in New York, New York, USA. Its last known market value was $3 M (January 2024); there is no current figure. It employs about 3 people.
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Petros Pharmaceuticals, Inc.
In December 2024, the Company determined to discontinue sales of Stendra® to wholesalers. Beginning in March 2025, the Company is no longer engaged in the commercialization, development or sales of Stendra®. In addition, on June 16, 2025, in accordance with California state law, the Company effected an assignment of all of the business, assets, properties, contractual rights, goodwill, going concern value, rights and claims of Metuchen, including Metuchen’s wholly-owned subsidiaries, Timm Medical and PTV and each of their respective Assets, for the benefit of creditors to a special purpose vehicle that is managed by a third-party fiduciary such that, as of June 16, 2025, the Assignee succeeded to all of each Subsidiary’s right, title and interest in and to the respective ABC Assets. Upon the completion of the Assignment, the Assignee obtained sole control over the ABC Assets and each Subsidiary no longer operates its business or controls the liquidation or distribution of its assets or the resolution of claims. The Assignment is a judicial insolvency procedure, which was commenced by each Subsidiary entering a contractual assignment for the benefit of creditors on June 16, 2025, that effectuates the assignment, grant, conveyance, transfer, and setting over to the Assignee, in trust, of all of the ABC Assets. Accordingly, the Company is no longer engaged in the marketing or selling of VEDs following the completion of the Assignment.
From the company's annual report filed with the US SEC: read the report
Petros Pharmaceuticals, Inc. timeline
- 2020
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
Events of Petros Pharmaceuticals, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #4,836 (Jan 2022) · #5,809 (Dec 2022) · #5,498 (Jul 2023) · #4,685 (Jan 2024)
Key ratios
- P/E ratio
- —
- Price / sales
- —
- Price / book
- —
- Free cash flow yield
- —
- Net margin
- —
- Operating margin
- —
- Return on equity
- 66.6%
- Liabilities / assets
- 44.4%
- Revenue growth
- -12.2%
- R&D / revenue
- 51.3%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | $-5M | $2M | — |
| Dec 2024 | $5M | -12.2% | $-5M | $-14M | -280.2% |
| Dec 2023 | $6M | -2.8% | $-14M | $-8M | -140.2% |
| Dec 2022 | $6M | -23.3% | $-20M | $-20M | -334.6% |
| Dec 2021 | $8M | -18.3% | $-18M | $-9M | -115.1% |
| Dec 2020 | $10M | — | $-17M | $-21M | -215.4% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-7M | — | — | $-1.56 | — |
| Dec 2024 | $-3M | $0M | $-3M | $-83.47 | — |
| Dec 2023 | $-8M | — | — | $-6.35 | — |
| Dec 2022 | $-13M | — | — | $-9.68 | — |
| Dec 2021 | $-12M | — | — | $-8.25 | — |
| Dec 2020 | $-15M | $0M | $-15M | $-3.85 | — |
Quarterly results
Latest quarter to Jun 2026: revenue —, net income $-1M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.
SEC filings
- Sep 30, 20268-KCurrent reportBankruptcy · Directors or officers changed
- Aug 13, 202610-QQuarterly report · period to Jun 2026
- Jun 18, 20268-KCurrent reportDirectors or officers changed
- Jun 5, 20268-KCurrent reportDirectors or officers changed
- May 13, 202610-QQuarterly report · period to Mar 2026
- Apr 15, 202610-KAnnual report · period to Dec 2025
- Jan 2, 20268-KCurrent reportDirectors or officers changed
- Nov 13, 202510-QQuarterly report · period to Sep 2025
- Nov 7, 20258-KCurrent reportListing notice
- Sep 5, 20258-KCurrent reportAuditor change
- Aug 14, 202510-QQuarterly report · period to Jun 2025
- Jun 20, 20258-KCurrent reportRegulation FD disclosure
Official filings of Petros Pharmaceuticals, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-5 M
- Net income
- $2 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $5 M
- Total liabilities
- $2 M
- Total equity
- $3 M
As of December-2025
Insider trading at Petros Pharmaceuticals, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Wayne Remell WalkerDirector | Grant or award | +375,000 | — | — | 881,333 | Form 4 |
| filed | Fady BoctorSee Remarks | Grant or award | +375,000 | — | — | 894,986 | Form 4 |
| filed | Joshua SilvermanDirector | Grant or award | +4.38 M | — | — | 8.79 M | Form 4 |
| filed | Bruce BernsteinDirector | Grant or award | +1.88 M | — | — | 3.76 M | Form 4 |
| filed | Fady BoctorSee Remarks | Grant or award | +500,000 | — | — | 519,986 | Form 4 |
| filed | Joshua SilvermanDirector | Grant or award | +4.38 M | — | — | 4.42 M | Form 4 |
| filed | Wayne Remell WalkerDirector | Grant or award | +500,000 | — | — | 506,333 | Form 4 |
| filed | Bruce BernsteinDirector | Grant or award | +1.88 M | — | — | 1.89 M | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Petros Pharmaceuticals, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-25 reverse split ; 1-for-10 reverse split ; 1-for-10 reverse split
Bankruptcy filing: (8-K)
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Petros Pharmaceuticals, Inc. scorecard#
Passes 3 of the 6 checks that could be worked out. Fiscal year 2025.
Valuationnot known
- –P/E below its peers' medianNo market cap.
- –Price to book below its peers' medianNo market cap.
- –Price to sales below its peers' medianNo market cap.
- –Free cash flow yield above 5%No market cap.
- –Earnings yield above the 10-year Treasury yieldNo market cap.
- –The price assumes slower growth than the last three years'No market cap.
Growth1 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-1.56 vs -83.47Diluted EPS -1.56 in fiscal 2025 against -83.47 the year before (report's currency).
- ✓Net income higher than five years earlier$2 M$2 M in fiscal 2025 against -$21 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability1 of 2
- ✓Profitable in the newest year$2 MNet income $2 M in fiscal 2025.
- ✗Profitable in each of the last five years1 of 5Profitable in 1 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- –Return on equity above 15%No return on equity (equity missing or negative).
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 2
- ✓Short-term assets cover short-term liabilities2.2×Current ratio 2.25 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returnsnot known
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- –Share count up no more than 2% in a yearShare counts of two years are not on file.
- –Dividends and buybacks above 3% of the market valueNo market cap.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (sec), the medians of Pharmaceutical, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Petros Pharmaceuticals, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | — | 5.1−12.2%100% | 5.8−2.8%100% | 6.0−23.3%100% | 7.8−18.3%100% | 9.6—100% | |
| Cost of revenue | — | 1.2−25.7%23.7% | 1.6−28.7%28.0% | 2.3+43.1%38.2% | 1.6−60.5%20.5% | 4.0—42.3% | |
| Gross profit | — | 3.9−7.0%76.3% | 4.2+13.2%72.0% | 3.7−40.4%61.8% | 6.2+12.7%79.5% | 5.5—57.7% | |
| Research and development | — | 2.6+8.5%51.2% | 2.4+38.4%41.4% | 1.7−2.7%29.0% | 1.8+289%22.9% | 0.5—4.8% | |
| Selling, general and administrative | 4.6+0.3%— | 4.6r8.7−50.0%90.5% | 9.3−24.1%159% | 12−21.7%204% | 16−0.5%200% | 16—164% | |
| Operating expenses | 4.6+0.3%— | 4.6r22−74.0%90.5% | 18−24.6%306% | 24−2.6%394% | 24+6.4%311% | 23—238% | |
| Operating income | −4.6—— | −4.6r−18—−90.5% | −14—−234% | −20—−332% | −18—−231% | −17—−181% | |
| Interest and finance income | — | — | — | 0.0—0.2% | — | — | |
| Interest expense and finance costs | — | 0.6+4.6%11.0% | 0.5−10.0%9.2% | 0.6+61.7%9.9% | 0.4−87.9%4.7% | 3.1—31.9% | |
| Net interest income | 0.3−30.9%— | 0.4−27.9%7.3% | 0.5+3530%8.9% | 0.0—0.2% | — | — | |
| Other non-operating income (expense) | 0.1−96.4%— | 3.9r3.4−28.1%76.7% | 5.5—93.7% | −0.1—−2.0% | — | — | |
| Income before tax | −4.5—— | −0.7r−14—−13.8% | −8.2—−140% | −20—−334% | −9.0—−115% | −22—−230% | |
| Income tax | 0—— | 0—0.0% | 0—0.0% | — | 0—0.0% | −1.4—−14.9% | |
| Income from continuing operations | −4.5—— | −0.7—−13.8% | — | — | — | — | |
| Income from discontinued operations | −0.6—— | −14—−266% | — | — | — | — | |
| Net income including minority interests | 1.9—— | −14—−280% | −8.2—−140% | −20—−334% | −9.0—−115% | −21—−215% | |
| Net income attributable to shareholders | 1.9—— | −14—−280% | −8.2—−140% | −20—−334% | −9.0—−115% | −21—−215% | |
| Earnings per share, basic | -1.56—— | -83.47r-3.34—— | -6.35—— | -9.68—— | -8.25r-0.83—— | -3.85—— | |
| Earnings per share, diluted | -1.56—— | -83.47r-3.34—— | -6.35—— | -9.68—— | -8.25r-0.83—— | -3.85—— | |
| Shares, weighted average (basic) | 28+8642%— | 0.3r8.0−85.2%— | 2.2+5.1%— | 2.1+90.1%— | 1.1r11−79.6%— | 5.3—— | |
| Shares, weighted average (diluted) | 28+8642%— | 0.3r8.0−85.2%— | 2.2+5.1%— | 2.1+90.1%— | 1.1r11−79.6%— | 5.3—— | |
| Balance sheet | |||||||
| Cash and cash equivalents | 5.1+199%99.5% | 1.7r3.7−87.1%16.2% | 13r13+41.5%39.5% | 9.4−60.5%29.1% | 24+39.1%35.4% | 17—24.5% | |
| Receivables | — | 0.4−81.3%3.9% | 2.2+5.5%6.6% | 2.1−14.1%6.5% | 2.5−52.4%3.6% | 5.2—7.4% | |
| Inventory | — | 1.3−16.2%12.7% | 1.6−11.3%4.8% | 1.8+249%5.6% | 0.5−31.7%0.8% | 0.8—1.1% | |
| Other current assets | 0.0+311%0.5% | 0.0−94.1%0.1% | 0.1−19.4%0.3% | 0.1+25.5%0.4% | 0.1−4.0%0.2% | 0.1—0.2% | |
| Current assets | 5.2−29.2%100% | 7.3−64.2%68.6% | 20+39.0%60.3% | 15−52.0%45.2% | 31+17.9%45.3% | 26—37.1% | |
| Property, plant and equipment | — | 0.0−20.8%0.2% | 0.0−26.1%0.1% | 0.0−20.7%0.1% | 0.0−23.1%0.1% | 0.1—0.1% | |
| Right-of-use (leased) assets | — | 0.1−49.7%1.1% | 0.2−36.9%0.7% | 0.4r0.4−24.6%1.1% | 0.5−17.9%0.7% | 0.6—0.8% | |
| Other intangible assets | — | 3.2−64.3%30.1% | 9.0−26.7%26.5% | 12−51.6%37.8% | 25−21.4%37.5% | 32—46.0% | |
| Total assets | 5.2−51.4%100% | 11−68.5%100% | 34+4.2%100% | 32−51.9%100% | 67−3.5%100% | 70—100% | |
| Accounts payable | 0.1−89.0%1.6% | 0.8r2.3−55.4%7.2% | 1.7−5.2%5.1% | 1.8−60.4%5.6% | 4.6—6.8% | — | |
| Debt due within a year | — | — | — | — | — | 7.2—10.3% | |
| Current liabilities | 2.3−87.3%44.4% | 18+67.4%170% | 11+52.4%31.9% | 7.1−77.2%21.8% | 31−26.1%46.0% | 42—60.0% | |
| Lease liabilities (non-current) | — | 0.1−45.4%0.7% | 0.1−47.6%0.4% | 0.3−35.1%0.8% | 0.4−23.7%0.6% | 0.5—0.8% | |
| Total liabilities | 2.3−87.3%44.4% | 18−15.1%170% | 21+35.6%63.1% | 16−50.6%48.5% | 32−39.2%47.3% | 52—75.0% | |
| Retained earnings | −111—−2155% | −113—−1064% | −99—−293% | −91—−280% | −71—−105% | −62—−88.3% | |
| Shareholders' equity | 2.9—55.6% | −7.5−162%−70.2% | 12−27.7%35.7% | 17−53.0%51.5% | 36+103%52.7% | 17—25.0% | |
| Total liabilities and equity | 5.2−51.4%100% | 11−68.5%100% | 34+4.2%100% | 32−51.9%100% | 67−3.5%100% | 70—100% | |
| Shares outstanding | 42+9941%— | 0.4r11−85.9%— | 3.0+43.9%— | 2.1+0.5%— | 2.1r21−78.7%— | 9.7—— | |
| Cash-flow statement | |||||||
| Depreciation and amortization | — | 2.8−13.8%55.4% | 3.3−41.4%56.4% | 5.6−18.6%93.4% | 6.9+3.3%88.1% | 6.7—69.7% | |
| Share-based compensation | 0.3+54.5%— | 0.2−52.7%3.9% | 0.4−65.1%7.2% | 1.2−8.4%19.9% | 1.3r1.1—16.7% | — | |
| Cash from operating activities | −6.7—— | −2.6—−50.9% | −7.6—−131% | −13—−214% | −12—−152% | −15—−160% | |
| Capital expenditure | — | −0.0—−0.5% | — | — | — | −0.0—−0.0% | |
| Cash from investing activities | — | −0.0—−0.5% | — | — | — | −0.0—−0.0% | |
| Debt repaid | — | — | — | — | −6.7—−85.2% | −6.2—−64.7% | |
| Shares issued | — | — | — | — | 22—278% | — | |
| Cash from financing activities | 8.2—— | −7.0−161%−137% | 12—198% | −1.6−109%−27.1% | 19−38.7%238% | 30—317% | |
| Change in cash | — | −9.6−346%−188% | 3.9—67.2% | −14−315%−241% | 6.7−55.3%85.9% | 15—157% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Jun 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 | Q3 FY2023to Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | — | — | — | — | — | — | — | 0.7*—100% | 1.6−5.9%100% | 1.4—100% | 1.4—100% | — | 1.7—100% | |
| Cost of revenue | — | — | — | — | — | — | — | 0.3*+67.4%36.5% | 0.3−29.7%18.2% | 0.3—23.2% | 0.3—23.9% | 0.2*—— | 0.4—24.4% | |
| Gross profit | — | — | — | — | — | — | — | 0.5*—63.5% | 1.3+1.8%81.8% | 1.1—76.8% | 1.1—76.1% | −0.5*—— | 1.3—75.6% | |
| Research and development | — | — | — | — | — | — | — | 0.1*−87.8%14.1% | 0.6+51.2%37.3% | 0.4—25.9% | 1.6—112% | 0.8*—— | 0.4—23.2% | |
| Selling, general and administrative | 3.4−32.5%— | 1.0−45.1%— | 1.0−29.6%— | 0.4*−32.2%— | 1.0−17.3%— | 1.8+33.5%— | 1.5−3.0%— | 0.6r1.4*−79.9%79.6% | 1.2r2.3−40.2%76.0% | 1.3r2.3—94.9% | 1.5r2.7—108% | 2.9*—— | 2.0—120% | |
| Operating expenses | 3.4−32.5%— | 1.0−45.1%— | 1.0−29.6%— | 0.4*−32.2%— | 1.0−17.3%— | 1.8+33.5%— | 1.5−3.0%— | 0.6r9.6*−87.2%79.6% | 1.2r3.6−80.3%76.0% | 1.3r3.4—94.9% | 1.5r5.0—108% | 4.5*—— | 6.1—363% | |
| Operating income | −3.4—— | −1.0—— | −1.0—— | −0.4*—— | −1.0—— | −1.8—— | −1.5—— | −0.6r−9.1*—−79.6% | −1.2r−2.3—−76.0% | −1.3r−2.3—−94.9% | −1.5r−3.9—−108% | −5.0*—— | −4.8—−287% | |
| Interest expense and finance costs | — | — | — | — | — | — | — | — | — | — | — | 0.1*—— | 0.1—7.8% | |
| Net interest income | 0.2−18.9%— | 0.0−64.0%— | 0.0−16.0%— | 0.1*+115%— | 0.1−11.6%— | 0.1−25.6%— | 0.0−68.5%— | 0.0*−89.1%3.4% | 0.1r0.1−55.0%4.8% | 0.1—8.4% | 0.2—10.9% | 0.2*—— | 0.2—10.1% | |
| Other non-operating income (expense) | 0.2−38.9%— | 0.0—— | 0.0−84.5%— | 0.1*+122%— | 0.1−75.5%— | −0.2−114%— | 0.3−86.3%— | 0.0r−0.1*−99.5%3.4% | 0.3r0.1+8.0%17.6% | 1.7r1.6—122% | 1.9r1.8—136% | 5.4*—— | 0.3—15.4% | |
| Income before tax | −3.2—— | −1.0—— | −1.0—— | −0.3*—— | −0.9—— | −2.0−631%— | −1.2−413%— | −0.6r−9.3*−274%−76.2% | −0.9r−2.2—−58.3% | 0.4r−0.7—27.0% | 0.4r−2.2—27.6% | 0.3*—— | −4.5—−272% | |
| Income from continuing operations | −3.2—— | −1.0—— | −1.0—— | −0.3*—— | −0.9—— | −2.0−631%— | −1.2−413%— | −0.6*—−76.2% | −0.9—−58.3% | 0.4—27.0% | 0.4—27.6% | — | — | |
| Income from discontinued operations | — | — | — | 0*—— | 0*—— | 0.5—— | −1.1—— | −8.7*—−1202% | −1.3—−82.5% | −1.0—−73.6% | −2.5—−183% | — | — | |
| Net income including minority interests | −3.2—— | −1.0*−118%— | −1.0—— | −0.3*—— | −0.9*—— | 5.4*—— | −2.3—— | −9.3*−3015%−1278% | −2.2*—−141% | −0.7*—−46.6% | −2.2—−156% | 0.3*—— | −4.5*—−272% | |
| Net income attributable to shareholders | −3.2—— | −1.0−118%— | −1.0—— | −0.3*—— | −0.9—— | 5.4—— | −2.3—— | −9.3*−3015%−1278% | −2.2—−141% | −0.7—−46.6% | −2.2—−156% | 0.3*—— | −4.5—−272% | |
| Earnings per share, basic | — | -0.30—— | -0.03—— | — | -0.03—— | -1.20r-1.29—— | -9.37—— | — | -16.65r-0.53—— | -9.25r-0.37—— | -42.19r-1.69—— | — | -2.85r-2.31—— | |
| Earnings per share, diluted | — | -0.30—— | -0.03—— | — | -0.03—— | -1.20r-1.29—— | -9.37—— | — | -16.65r-0.53—— | -9.25r-0.37—— | -42.19r-1.69—— | — | -2.85r-2.31—— | |
| Shares, weighted average (basic) | 47+82.8%— | 47+82.8%— | 46+3879%— | — | 42+10654%— | 26+8672%— | 1.2+511%— | — | 0.4r9.8−81.4%— | 0.3r7.4—— | 0.2r4.8—— | — | 2.1—— | |
| Shares, weighted average (diluted) | 47+82.8%— | 47+82.8%— | 46+3879%— | — | 42+10654%— | 26+8672%— | 1.2+511%— | — | 0.4r9.8−81.4%— | 0.3r7.4—— | 0.2r4.8—— | — | 2.1—— | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 3.5—98.4% | 3.5−52.4%98.4% | 4.4−51.3%99.0% | 5.1+199%99.5% | 6.1+55.6%99.0% | 7.3−2.4%99.0% | 8.9−19.5%50.7% | 1.7r3.7−87.1%16.2% | 3.9−78.3%18.8% | 7.5—29.8% | 11—36.6% | 13r13—39.5% | 18—46.3% | |
| Receivables | — | — | — | — | — | — | — | 0.4−81.3%3.9% | 1.9−34.5%9.4% | 1.8—7.1% | 2.0—6.5% | 2.2—6.6% | 3.0—7.6% | |
| Inventory | — | — | — | — | — | — | — | 1.3−16.2%12.7% | 1.4−43.8%6.8% | 1.4—5.7% | 1.6—5.1% | 1.6—4.8% | 2.5—6.4% | |
| Other current assets | 0.1—1.6% | 0.1—1.6% | 0.0—1.0% | 0.0+311%0.5% | — | — | — | 0.0−94.1%0.1% | 0.0−91.7%0.0% | 0.1—0.3% | 0.1—0.3% | 0.1—0.3% | 0.1—0.1% | |
| Current assets | 3.5—100% | 3.5−52.1%100% | 4.4−69.6%100% | 5.2−29.2%100% | 6.1−42.8%100% | 7.4−47.1%100% | 14−19.2%82.2% | 7.3−64.2%68.6% | 11−56.1%51.8% | 14—55.5% | 18—59.1% | 20—60.3% | 24—62.8% | |
| Property, plant and equipment | — | — | — | — | — | — | — | 0.0−20.8%0.2% | 0.0−40.3%0.1% | 0.0—0.1% | 0.0—0.1% | 0.0—0.1% | 0.0—0.1% | |
| Right-of-use (leased) assets | — | — | — | — | — | — | — | 0.1−49.7%1.1% | 0.1−52.1%0.6% | 0.2—0.6% | 0.2—0.6% | 0.2—0.7% | 0.3—0.7% | |
| Other intangible assets | — | — | — | — | — | — | — | 3.2−64.3%30.1% | 6.8−30.1%33.0% | 7.5—30.0% | 8.3—27.2% | 9.0—26.5% | 9.8—25.1% | |
| Total assets | 3.5—100% | 3.5−52.1%100% | 4.4−75.0%100% | 5.2−51.4%100% | 6.1−70.4%100% | 7.4−70.6%100% | 18−41.9%100% | 11−68.5%100% | 21−46.8%100% | 25—100% | 30—100% | 34—100% | 39—100% | |
| Accounts payable | 0.1—2.7% | 0.1−90.0%2.7% | 0.1−82.4%3.0% | 0.1−89.0%1.6% | 0.4−73.7%6.9% | 1.0+22.6%13.1% | 0.8−64.6%4.3% | 0.8r2.3−55.4%7.2% | 1.6+18.1%7.7% | 0.8—3.1% | 2.1—7.1% | 1.7—5.1% | 1.4—3.5% | |
| Current liabilities | 2.8—80.2% | 2.8−3.6%80.2% | 2.6−90.3%59.7% | 2.3−87.3%44.4% | 2.8−78.0%45.1% | 2.9−70.4%39.9% | 27+142%154% | 18+67.4%170% | 13+55.4%60.7% | 10.0—39.6% | 11—37.0% | 11—31.9% | 8.1—20.8% | |
| Lease liabilities (non-current) | — | — | — | — | — | — | — | 0.1−45.4%0.7% | — | — | — | 0.1—0.4% | 0.2—0.4% | |
| Total liabilities | 2.8—80.2% | 2.8−3.6%80.2% | 2.6−90.4%59.7% | 2.3−87.3%44.4% | 2.8−84.3%45.1% | 2.9−81.5%39.9% | 27+38.6%154% | 18−15.1%170% | 18−44.8%84.9% | 16—63.5% | 20—64.7% | 21—63.1% | 32—81.9% | |
| Retained earnings | −113—−3194% | −113—−3194% | −112—−2555% | −111—−2155% | −111—−1809% | −110—−1488% | −115—−656% | −113—−1064% | −104—−502% | −102—−404% | −101—−333% | −99—−293% | −99—−255% | |
| Shareholders' equity | 0.7—19.8% | 0.7−84.2%19.8% | 1.8—40.3% | 2.9—55.6% | 3.4+8.1%54.9% | 4.4−44.9%60.1% | −9.6−198%−54.4% | −7.5−162%−70.2% | 3.1−55.1%15.1% | 8.1—32.1% | 9.8—32.3% | 12—35.7% | 6.9—17.8% | |
| Total liabilities and equity | 3.5—100% | 3.5−52.1%100% | 4.4−75.0%100% | 5.2−51.4%100% | 6.1−70.4%100% | 7.4−70.6%100% | 18−41.9%100% | 11−68.5%100% | 21−46.8%100% | 25—100% | 30—100% | 34—100% | 39—100% | |
| Shares outstanding | 42—— | 42+0.2%— | 42+1964%— | 42+9941%— | 42+322%— | 42+355%— | 2.1−70.2%— | 0.4r11−85.9%— | 10+372%— | 9.3—— | 6.9—— | 3.0—— | 2.1—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | — | — | — | — | — | — | — | 0.7*−18.3%90.4% | 0.7−10.6%46.9% | 0.7—50.5% | 0.7—51.7% | 0.8*—— | 0.8—49.4% | |
| Share-based compensation | — | 0.1*+58.6%— | 0.1+50.3%— | — | — | 0.1*+341%— | 0.1−55.6%— | 0*−100%0.0% | 0−100%0.0% | 0.0—1.2% | 0.2—13.0% | 0.2*—— | 0.0—1.8% | |
| Cash from operating activities | −3.7—— | −0.9*—— | −0.8—— | −0.9*−197%— | −1.1*—— | −3.0*—— | −1.7—— | 1.0*—133% | −0.8*—−48.9% | −1.7*—−117% | −1.1—−81.7% | −2.3*—— | −4.0*—−242% | |
| Capital expenditure | — | — | — | — | — | — | — | −0.0*—−0.8% | — | — | — | — | — | |
| Cash from investing activities | — | — | — | — | — | — | — | −0.0*—−0.8% | — | — | — | — | — | |
| Cash from financing activities | — | — | — | 0*—— | −0.1*—— | −0.4*—— | 8.7—— | −1.1*—−158% | −2.8*−119%−176% | −2.0*—−138% | −1.1—−80.7% | −2.4*—— | 15*—874% | |
| Change in cash | — | — | — | — | — | — | — | −0.2*—−25.5% | −3.6*−134%−226% | −3.6*—−255% | −2.3—−162% | −4.6*—— | 11*—632% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Jun 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Events at Petros Pharmaceuticals, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
- Bankruptcy or receivershipDebt called earlyFiling
- Delisting noticeFiling
- Auditor changedFiling
- Delisting noticeFiling
- Delisting noticeFiling
- Delisting noticeFiling
And 3 more in the list below.
Bankruptcy or receivership 1 · Delisting notice 4 · Auditor changed 3 · Debt called early 2 · Directors and officers 7 · Material agreement 4 · Shareholder rights changed 4 · Bylaws or fiscal year changed 4 · Shareholder vote 2
| Filed | What happened | Filing |
|---|---|---|
| Bankruptcy or receivershipDebt called earlyDirectors and officers | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Delisting notice | 8-K | |
| Auditor changed | 8-K | |
| Delisting notice | 8-K | |
| Delisting noticeShareholder rights changedBylaws or fiscal year changed | 8-K | |
| Delisting noticeDirectors and officersShareholder rights changedBylaws or fiscal year changedShareholder vote | 8-K | |
| Auditor changed | 8-K | |
| Material agreement | 8-K | |
| Material agreementShareholder rights changedBylaws or fiscal year changed | 8-K | |
| Debt called early | 8-K | |
| Shareholder vote | 8-K | |
| Directors and officers | 8-K | |
| Material agreementShareholder rights changedBylaws or fiscal year changed | 8-K | |
| Directors and officers | 8-K | |
| Material agreement | 8-K | |
| Auditor changed | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Sep 30, 2026
Acquisitions and funding#
2 private funding rounds before listing
Private share sales · funding history
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
How Petros Pharmaceuticals, Inc. compares in Pharmaceutical
- Revenue growth-12.2% · higher than 11% of 107
Peer comparison · Pharmaceutical
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Petros Pharmaceuticals, Inc.🇺🇸 | $3 M | — | — | -12.2% |
| Eli Lilly and Company🇺🇸 | $1.20 T | 43.4× | 31.9% | +44.7% |
| Johnson & Johnson🇺🇸 | $652.5 B | 40.5× | 16.2% | +6.0% |
| AbbVie Inc.🇺🇸 | $514.0 B | 49.7× | 15.7% | +8.6% |
| Roche Holding AG🇨🇭 | $370.3 B | 29.1× | 19.0% | — |
| Merck & Co., Inc.🇺🇸 | $359.8 B | 146.7× | 3.6% | +1.3% |
| Novartis AG🇨🇭 | $286.8 B | 20.5× | 24.7% | — |
| Amgen Inc.🇺🇸 | $249.2 B | 26.5× | 24.1% | +9.9% |
| AstraZeneca PLC🇬🇧 | $242.6 B | 23.7× | 17.4% | +8.6% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Eli Lilly and Company$1.20 T
- Johnson & Johnson$652.5 B
- AbbVie Inc.$514.0 B
- Roche Holding AG$370.3 B
- Merck & Co., Inc.$359.8 B
- Novartis AG$286.8 B
Sources and freshness
- Market cap:
- Jan 5, 2024 (last known)
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of December 31, 2025
- Profile updated:
- Nov 16, 2026
Figures from SEC filing, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Petros Pharmaceuticals, Inc.? Verify and update this profile — free
Show Petros Pharmaceuticals, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.